RxDoctor Payments Data

Lauren Dedea, MD

Family Medicine · Spring Hill, FLNPI 1053722009

Payments from drug & device makers

$2,300in general payments, 2019–2025

Across 80 payments — averaging $28.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$421
  • Boehringer Ingelheim$307
  • Johnson & Johnson$276
  • AbbVie$272
  • Lilly USA, LLC$255
  • AstraZeneca$172
  • plus $598 from 12 others

What the payments were for

  • Food & beverage$2,26598%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,300 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$43,238
Medicare patients
94
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$27,951
Repatha SureclickEvolocumab26$20,694
SynthroidLevothyroxine Sodium16$1,287
Levothyroxine Sodium77$899
Duloxetine Hcl24$726
Rosuvastatin Calcium59$575
Atorvastatin Calcium48$412
Lisinopril59$396
Omeprazole22$391
Escitalopram Oxalate18$300
Metoprolol Succinate30$293
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$284
Gabapentin12$272
Simvastatin47$271
Pantoprazole Sodium19$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$255$27,95117 claims
AbbVieSynthroid$272$1,28716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →